| Outcome Measures: |
Primary: Viral Load, Assess differences in SARS-CoV-2 viral load between participants that receive placebo vs metformin glycinate, Day 0 to Day 8 or patient discharge day | Secondary: Days of supplementary oxygen if apply, Assess length of supplementary oxygen, Day 0 to day 28 or patient discharge day|Days of supplementary mechanical ventilation if apply, Assess length of mechanical ventilation, Day 0 to day 28 or patient discharge day|Days of Hospitalization, Assess length of hospitalization, Day 0 to day 28 or patients discharge day|Normalization of fever, Assess the difference in the Proportion of participants with normalization of fever between participants that receive placebo vs the patients with metformin glycinate, Day 0 to day 28 or patient discharge day|Normalization of oxigen saturation, Assess the difference in the Proportion of participants with normalization of oxygen saturation between participants that receive placebo vs the patients with metformin glycinate, Day 0 to day 28 or patient discharge day|Number of deaths, Assess the difference in the number of deaths between participants who received placebo versus the patients with metformin glycinate, Day 0 to day 28 or patient discharge day|Change in Serum creatinine levels, Evaluate if the level increase or decrease in serum creatinine compared to baseline. units: mg/dl, Day 0 to day 28 or patients discharge day|Change in serum Troponin I, Evaluate if the level increase or decrease in serum Creatine kinase-MB compared to baseline. Units: UI/l, Day 0 to day 28 or patients discharge day|Change in serum aspartate aminotransferase levels, Evaluate if the level increase or decrease in serum aspartate aminotransferase compared to baseline. units: IU/l, Day 0 to day 28 or patients discharge day|Change in serum Creatine kinase-MB levels, Evaluate if the level increase or decrease in serum Creatine kinase-MB compared to baseline. Units: UI/l, Day 0 to day 28 or patients discharge day|Incidence of adverse event, Assess by incidence of grade 3, grade 4 and Serious adverse events, Day 0 to day 28 or patients discharge day
|
